[PubMed 25705229]

4. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention.
https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf. Updated 2020.
Accessed May 6, 2020.

5. González-Medina M, Curto-Barredo L, Labrador-Horrillo M, Giménez-Arnau A. Omalizumab use during pregnancy

for chronic spontaneous urticaria (CSU): report of two cases. J Eur Acad Dermatol Venereol. 2017;31(5):e245-e246.
doi: 10.1111/jdv.14034. [PubMed 27868240]

6. Institute for Safe Medication Practices (ISMP). ISMP medication safety alert, acute care
https://www.ismp.org/newsletters/acute-care. Updated 2019. Accessed September 13, 2019.

7. Kupryś-Lipińska I, Tworek D, Kuna P. Omalizumab in pregnant women treated due to severe asthma: two case
reports of good outcomes of pregnancies. Postepy Dermatol Alergol. 2014;31(2):104-107. doi:
10.5114/pdia.2014.40975. [PubMed 25097476]

8. Lieberman P, Nicklas RA, Randolph C, et al. Anaphylaxis--a practice parameter update 2015. Ann Allergy Asthma
Immunol. 2015;115(5):341-384. doi: 10.1016/j.anai.2015.07.019. [PubMed 26505932]

9. Middleton PG, Gade EJ, Aguilera C, et al. ERS/TSANZ Task Force Statement on the management of reproduction
and pregnancy in women with airways diseases. Eur Respir J. 2020;55(2):1901208. doi:10.1183/13993003.01208-
2019 [PubMed 31699837]

10. Namazy J, Cabana MD, Scheuerle AE, et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use
during pregnancy. J Allergy Clin Immunol. 2015;135(2):407-412. doi: 10.1016/j.jaci.2014.08.025. [PubMed
25441639]

11. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and
pathological pregnancies. Clin Dev Immunol. 2012;2012:985646. doi: 10.1155/2012/985646. [PubMed 22235228]

12. Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into
developmental toxicity testing of monoclonal antibodies. Birth Defects Res B Dev Reprod Toxicol. 2009;86(4):328-
344. doi: 10.1002/bdrb.20201. [PubMed 19626656]

13. Xolair (omalizumab) [prescribing information]. South San Francisco, CA: Genentech Inc; April 2021.
14. Xolair (omalizumab) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc;
September 2017.

Topic 10251 Version 191.0